KCNK3 and pulmonary arterial hypertension: On the other hand, designing TASK-1 blockers that do not block heteromeric TASK-1/TASK-5 channels should be beneficial for the treatment of AFib, as this will bypass the side effect of PAH discussed for TASK-1 blockers42,43.